The law offices of frank r. cruz continues investigation of regeneron pharmaceuticals, inc. (regn) on behalf of investors

Los angeles, nov. 25, 2024 (globe newswire) -- the law offices of frank r. cruz continues its investigation of regeneron pharmaceuticals, inc. (“regeneron” or the “company”) (nasdaq: regn) on behalf of investors concerning the company's possible violations of federal securities laws.

REGN Ratings Summary

REGN Quant Ranking